Operating
Amortization of Investment Discount and Premium
Neurocrine Biosciences Amortization of Investment Discount and Premium decreased by 35.0% to $1.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 71.7%, from $4.60M to $1.30M. Over 4 years (FY 2021 to FY 2025), Amortization of Investment Discount and Premium shows an upward trend with a 14.5% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
Changes reflect shifts in the yield profile of the company's investment portfolio rather than operational performance.
Detailed definition
This metric represents the non-cash adjustment for the amortization of premiums or the accretion of discounts on marketa...
Peer comparison
Standard for companies with large treasury or finance divisions; peers report this as part of the reconciliation of net income to operating cash flow.
Metric ID:
anet_investment_income_amortizationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$1.85M | -$1.85M | -$1.85M | -$925.00K | -$925.00K | -$925.00K | -$925.00K | $2.10M | $3.90M | $6.00M | $6.30M | $7.10M | $7.00M | $6.50M | $5.60M | $4.60M | $3.40M | $2.70M | $2.00M | $1.30M |
| QoQ Change | — | +0.0% | +0.0% | +50.0% | +0.0% | +0.0% | +0.0% | +327.0% | +85.7% | +53.8% | +5.0% | +12.7% | -1.4% | -7.1% | -13.8% | -17.9% | -26.1% | -20.6% | -25.9% | -35.0% |
| YoY Change | — | — | — | — | +50.0% | +50.0% | +50.0% | +327.0% | +521.6% | +748.6% | +781.1% | +238.1% | +79.5% | +8.3% | -11.1% | -35.2% | -51.4% | -58.5% | -64.3% | -71.7% |
Range-$1.85M – $7.10M
CAGR-7.2%
Avg YoY Growth+160.1%
Median YoY Growth+50.0%
Current Streak8 quarters decline
Amortization of Investment Discount and Premium at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's amortization of investment discount and premium?
- Neurocrine Biosciences (NBIX) reported amortization of investment discount and premium of $1.30M in Q1 2026.
- How has Neurocrine Biosciences's amortization of investment discount and premium changed year-over-year?
- Neurocrine Biosciences's amortization of investment discount and premium decreased by 71.7% year-over-year, from $4.60M to $1.30M.
- What is the long-term trend for Neurocrine Biosciences's amortization of investment discount and premium?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's amortization of investment discount and premium has grown at a 14.5% compound annual growth rate (CAGR), from -$7.40M to $12.70M.
- What does amortization of investment discount and premium mean?
- The non-cash adjustment for the difference between interest income earned and cash interest received on investments.